MD Anderson registers Phase II trial of Summit's ivonescimab in rare appendix cancer
A new Phase II study will test Summit Therapeutics' ivonescimab with intraperitoneal paclitaxel in metastatic appendiceal adenocarcinoma, with Summit listed as a collaborator.
This week's sole update concerns a newly registered trial involving Summit Therapeutics' ivonescimab.
- A Phase II study titled "A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)" is not yet recruiting, with an estimated start of 2027-01-16.1 The trial is sponsored by M.D. Anderson Cancer Center, with Cancer Prevention Research Institute of Texas and Summit Therapeutics listed as collaborators.1 The study aims to evaluate the safety and effectiveness of ivonescimab combined with intraperitoneal paclitaxel (IP PTX) in patients with unresectable metastatic high-grade Appendiceal Adenocarcinoma (AA).1 The primary objective is to evaluate the safety and efficacy as measured by the disease control rate (DCR) of ivonescimab combined with IP PTX in patients with unresectable metastatic high-grade AA.1 Planned enrollment is 30 participants (estimated)1 in a phase2, single group1 design.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.